Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Neurocrine downgraded to Neutral from Buy at Goldman Sachs » 05:58
06/29/20
06/29
05:58
06/29/20
05:58
NBIX

Neurocrine

$130.44 /

+2.11 (+1.64%)

Goldman Sachs analyst…

Goldman Sachs analyst Paul Choi downgraded Neurocrine Biosciences to Neutral from Buy with an unchanged price target of $135. Neurocrine remains a "high quality name," but one that is transitioning from a company leveraged primarily to Ingrezza to a multi-product diversification play, Choi tells investors in a research note. The company's pipeline consists of an "attractive mix" of early, mid, and late stage assets, adds the analyst. However, absent more clarity on intermediate term Ingrezza growth or catalysts to further de-risk the pipeline, Choi sees Neurocrine's valuation and risk/reward as fairly balanced versus peers.

ShowHide Related Items >><<
NBIX Neurocrine
$130.44 /

+2.11 (+1.64%)

NBIX Neurocrine
$130.44 /

+2.11 (+1.64%)

06/26/20 Citi
Neurocrine price target raised to $149 from $124 at Citi
06/18/20 JPMorgan
Neurocrine price target raised to $134 from $122 at JPMorgan
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
NBIX Neurocrine
$130.44 /

+2.11 (+1.64%)

NBIX Neurocrine
$130.44 /

+2.11 (+1.64%)

Over a week ago
Recommendations
Neurocrine price target raised to $149 from $124 at Citi » 06:27
06/26/20
06/26
06:27
06/26/20
06:27
NBIX

Neurocrine

$128.33 /

+2.98 (+2.38%)

Citi analyst Neena…

Citi analyst Neena Bitritto-Garg raised the firm's price target on Neurocrine Biosciences to $149 from $124 and reiterates a Buy rating on the shares. With multiple approvals, exercise of the licensing option with Idorsia, the recent Takeda collaboration, crinecerfont Phase 2 data, and recent physician survey work suggesting there remains "significant room for growth" in Ingrezza uptake, "it is just a matter of when and not if" Neurocrine becomes a large, global biotech company, Bitritto-Garg tells investors in a research note. The analyst sees the Neurocrine story as "increasingly derisked and compelling from a long-term cash-flow generation perspective."

ShowHide Related Items >><<
NBIX Neurocrine
$128.33 /

+2.98 (+2.38%)

NBIX Neurocrine
$128.33 /

+2.98 (+2.38%)

06/18/20 JPMorgan
Neurocrine price target raised to $134 from $122 at JPMorgan
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
06/17/20 H.C. Wainwright
Neurocrine price target raised to $131 from $125 at H.C. Wainwright
NBIX Neurocrine
$128.33 /

+2.98 (+2.38%)

NBIX Neurocrine
$128.33 /

+2.98 (+2.38%)

Conference/Events
BofA to hold a virtual conference » 04:55
06/24/20
06/24
04:55
06/24/20
04:55
ALXN

Alexion

$115.44 /

-1.47 (-1.26%)

, JNJ

Johnson & Johnson

$142.86 /

-0.52 (-0.36%)

, NBIX

Neurocrine

$127.61 /

+0.17 (+0.13%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, SRPT

Sarepta

$168.86 /

-3 (-1.75%)

, ALNY

Alnylam

$152.00 /

-0.91 (-0.60%)

, BTAI

BioXcel Therapeutics

$58.53 /

+1.57 (+2.76%)

Napa Healthcare Virtual…

Napa Healthcare Virtual Conference will be held on June 22-24.

ShowHide Related Items >><<
SRPT Sarepta
$168.86 /

-3 (-1.75%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.61 /

+0.17 (+0.13%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

ALNY Alnylam
$152.00 /

-0.91 (-0.60%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
NBIX Neurocrine
$127.61 /

+0.17 (+0.13%)

06/18/20 JPMorgan
Neurocrine price target raised to $134 from $122 at JPMorgan
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
06/17/20 H.C. Wainwright
Neurocrine price target raised to $131 from $125 at H.C. Wainwright
RHHBY Roche
$0.00 /

+ (+0.00%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
SRPT Sarepta
$168.86 /

-3 (-1.75%)

06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
ALNY Alnylam
$152.00 /

-0.91 (-0.60%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

06/05/20 Guggenheim
Guggenheim starts BioXcel Therapeutics at Buy on optimistic view of lead asset
06/04/20 Guggenheim
BioXcel Therapeutics initiated with a Buy at Guggenheim
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
BioXcel Therapeutics initiated with a Buy at BofA
SRPT Sarepta
$168.86 /

-3 (-1.75%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.61 /

+0.17 (+0.13%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

ALNY Alnylam
$152.00 /

-0.91 (-0.60%)

SRPT Sarepta
$168.86 /

-3 (-1.75%)

RHHBY Roche
$0.00 /

+ (+0.00%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

ALNY Alnylam
$152.00 /

-0.91 (-0.60%)

SRPT Sarepta
$168.86 /

-3 (-1.75%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.61 /

+0.17 (+0.13%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

Conference/Events
BofA to hold a virtual conference » 04:55
06/23/20
06/23
04:55
06/23/20
04:55
ALXN

Alexion

$116.91 /

-2.36 (-1.98%)

, JNJ

Johnson & Johnson

$143.38 /

-0.63 (-0.44%)

, NBIX

Neurocrine

$127.44 /

-0.65 (-0.51%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, SRPT

Sarepta

$171.86 /

+3.36 (+1.99%)

, ALNY

Alnylam

$152.91 /

+3.23 (+2.16%)

, BTAI

BioXcel Therapeutics

$56.96 /

+4.27 (+8.10%)

Napa Healthcare Virtual…

Napa Healthcare Virtual Conference will be held on June 22-24.

ShowHide Related Items >><<
SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.44 /

-0.65 (-0.51%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

ALNY Alnylam
$152.91 /

+3.23 (+2.16%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/29/20 Barclays
Johnson & Johnson price target raised to $182 from $173 at Barclays
NBIX Neurocrine
$127.44 /

-0.65 (-0.51%)

06/18/20 JPMorgan
Neurocrine price target raised to $134 from $122 at JPMorgan
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
06/17/20 H.C. Wainwright
Neurocrine price target raised to $131 from $125 at H.C. Wainwright
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
ALNY Alnylam
$152.91 /

+3.23 (+2.16%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

06/05/20 Guggenheim
Guggenheim starts BioXcel Therapeutics at Buy on optimistic view of lead asset
06/04/20 Guggenheim
BioXcel Therapeutics initiated with a Buy at Guggenheim
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
BioXcel Therapeutics initiated with a Buy at BofA
SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.44 /

-0.65 (-0.51%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

ALNY Alnylam
$152.91 /

+3.23 (+2.16%)

SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

ALNY Alnylam
$152.91 /

+3.23 (+2.16%)

SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.44 /

-0.65 (-0.51%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

Conference/Events
BofA to hold a virtual conference » 08:54
06/22/20
06/22
08:54
06/22/20
08:54
ALXN

Alexion

$119.27 /

+3 (+2.58%)

, JNJ

Johnson & Johnson

$144.01 /

+0.46 (+0.32%)

, NBIX

Neurocrine

$128.09 /

+7.06 (+5.83%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, SRPT

Sarepta

$168.50 /

+3.27 (+1.98%)

, ALNY

Alnylam

$149.68 /

+7.67 (+5.40%)

, BTAI

BioXcel Therapeutics

$52.69 /

-2.16 (-3.94%)

Napa Healthcare Virtual…

Napa Healthcare Virtual Conference will be held on June 22-24.

ShowHide Related Items >><<
SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$128.09 /

+7.06 (+5.83%)

JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

BTAI BioXcel Therapeutics
$52.69 /

-2.16 (-3.94%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

ALNY Alnylam
$149.68 /

+7.67 (+5.40%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/29/20 Barclays
Johnson & Johnson price target raised to $182 from $173 at Barclays
NBIX Neurocrine
$128.09 /

+7.06 (+5.83%)

06/18/20 JPMorgan
Neurocrine price target raised to $134 from $122 at JPMorgan
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
06/17/20 H.C. Wainwright
Neurocrine price target raised to $131 from $125 at H.C. Wainwright
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
06/08/20 Piper Sandler
Sarepta limb-girdle muscular dystrophy data 'look great,' says Piper Sandler
ALNY Alnylam
$149.68 /

+7.67 (+5.40%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
BTAI BioXcel Therapeutics
$52.69 /

-2.16 (-3.94%)

06/05/20 Guggenheim
Guggenheim starts BioXcel Therapeutics at Buy on optimistic view of lead asset
06/04/20 Guggenheim
BioXcel Therapeutics initiated with a Buy at Guggenheim
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
BioXcel Therapeutics initiated with a Buy at BofA
SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$128.09 /

+7.06 (+5.83%)

JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

BTAI BioXcel Therapeutics
$52.69 /

-2.16 (-3.94%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

ALNY Alnylam
$149.68 /

+7.67 (+5.40%)

SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

RHHBY Roche
$0.00 /

+ (+0.00%)

JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

ALNY Alnylam
$149.68 /

+7.67 (+5.40%)

SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$128.09 /

+7.06 (+5.83%)

JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

BTAI BioXcel Therapeutics
$52.69 /

-2.16 (-3.94%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

BTAI BioXcel Therapeutics
$52.69 /

-2.16 (-3.94%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

Recommendations
Neurocrine price target raised to $134 from $122 at JPMorgan » 09:15
06/18/20
06/18
09:15
06/18/20
09:15
NBIX

Neurocrine

$119.30 /

+0.32 (+0.27%)

JPMorgan analyst Anupam…

JPMorgan analyst Anupam Rama raised the firm's price target on Neurocrine Biosciences to $134 from $122 and reiterates an Overweight rating on the shares after conducting a survey of 25 U.S. physicians to assess the near- and long-term potential of Ingrezza for the treatment of tardive dyskinesia. Surprisingly, nearly half of physicians specified in-line or similar amount of Ingrezza new scripts despite COVID-19 disruptions, Rama tells investors in a research note. The analyst had anticipated the majority of physicians would have a decline in new scripts volume. Further, nearly all physicians indicated that there have been no reimbursement hurdles to date, adds Rama. The analyst believes that longer-term, the physician survey results continue to support the potential of Ingrezza.

ShowHide Related Items >><<
NBIX Neurocrine
$119.30 /

+0.32 (+0.27%)

NBIX Neurocrine
$119.30 /

+0.32 (+0.27%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
06/17/20 H.C. Wainwright
Neurocrine price target raised to $131 from $125 at H.C. Wainwright
06/09/20 Wedbush
Wedbush bullish on Neurocrine, initiates with an Outperform
NBIX Neurocrine
$119.30 /

+0.32 (+0.27%)

NBIX Neurocrine
$119.30 /

+0.32 (+0.27%)

Recommendations
Neurocrine price target raised to $135 from $116 at RBC Capital » 06:58
06/18/20
06/18
06:58
06/18/20
06:58
NBIX

Neurocrine

$119.30 /

+0.32 (+0.27%)

, TAK

Takeda Pharmaceutical

$18.65 /

-0.51 (-2.66%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams raised the firm's price target on Neurocrine (NBIX) to $135 from $116 and keeps an Outperform rating on the shares. The analyst is updating his valuation model after a "string of favorable pipeline events" that include approvals of Ongentys/Oriahnn, promising congenital adrenal hyperplasia phase 2 data, and collaboration with Takeda (TAK) on psychiatric disorder therapies announced earlier this week. Abrahams adds that he continues to see an attractive overall long-term picture for Neurocrine given the likelihood of Ingrezza's return to growth.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$18.65 /

-0.51 (-2.66%)

NBIX Neurocrine
$119.30 /

+0.32 (+0.27%)

NBIX Neurocrine
$119.30 /

+0.32 (+0.27%)

06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
06/17/20 H.C. Wainwright
Neurocrine price target raised to $131 from $125 at H.C. Wainwright
06/09/20 Wedbush
Wedbush bullish on Neurocrine, initiates with an Outperform
06/09/20 Oppenheimer
Neurocrine price target raised to $142 from $130 at Oppenheimer
TAK Takeda Pharmaceutical
$18.65 /

-0.51 (-2.66%)

04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
03/25/20 Stifel
Molecular Templates initiated with a Buy at Stifel
TAK Takeda Pharmaceutical
$18.65 /

-0.51 (-2.66%)

NBIX Neurocrine
$119.30 /

+0.32 (+0.27%)

TAK Takeda Pharmaceutical
$18.65 /

-0.51 (-2.66%)

TAK Takeda Pharmaceutical
$18.65 /

-0.51 (-2.66%)

NBIX Neurocrine
$119.30 /

+0.32 (+0.27%)

TAK Takeda Pharmaceutical
$18.65 /

-0.51 (-2.66%)

Recommendations
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer » 07:25
06/17/20
06/17
07:25
06/17/20
07:25
NBIX

Neurocrine

$118.98 /

+3.91 (+3.40%)

, TAK

Takeda Pharmaceutical

$19.16 /

+0.78 (+4.24%)

Oppenheimer analyst Jay…

Oppenheimer analyst Jay Olson notes that in a landmark deal with Takeda (TAK), Neurocrine (NBIX) paid $120M upfront with up to $1.9B in milestones plus royalties to expand into psychiatry with three mid-stage clinical assets and four undisclosed preclinical assets. The analyst considers this collaboration an integral part of a prudent BD strategy following similar deals as he notes synergies with existing Ingrezza prescribers. Olson maintains an Outperform rating and $142 price target on Neurocrine's shares.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$19.16 /

+0.78 (+4.24%)

NBIX Neurocrine
$118.98 /

+3.91 (+3.40%)

NBIX Neurocrine
$118.98 /

+3.91 (+3.40%)

06/17/20 H.C. Wainwright
Neurocrine price target raised to $131 from $125 at H.C. Wainwright
06/09/20 Wedbush
Wedbush bullish on Neurocrine, initiates with an Outperform
06/09/20 Oppenheimer
Neurocrine price target raised to $142 from $130 at Oppenheimer
06/08/20 Wedbush
Neurocrine initiated with an Outperform at Wedbush
TAK Takeda Pharmaceutical
$19.16 /

+0.78 (+4.24%)

04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
03/25/20 Stifel
Molecular Templates initiated with a Buy at Stifel
02/25/20 Stifel
Iovance among 'more interesting' cell therapy takeout candidates, says Stifel
TAK Takeda Pharmaceutical
$19.16 /

+0.78 (+4.24%)

NBIX Neurocrine
$118.98 /

+3.91 (+3.40%)

TAK Takeda Pharmaceutical
$19.16 /

+0.78 (+4.24%)

TAK Takeda Pharmaceutical
$19.16 /

+0.78 (+4.24%)

NBIX Neurocrine
$118.98 /

+3.91 (+3.40%)

TAK Takeda Pharmaceutical
$19.16 /

+0.78 (+4.24%)

Recommendations
Neurocrine price target raised to $131 from $125 at H.C. Wainwright » 06:18
06/17/20
06/17
06:18
06/17/20
06:18
NBIX

Neurocrine

$118.98 /

+3.91 (+3.40%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein raised the firm's price target on Neurocrine Biosciences (NBIX) to $131 from $125 and reiterates a Buy rating on the shares after the company announced a strategic collaboration with Takeda Pharmaceutical (TAK). The collaboration as further validates Neurocrine's aptitude for the development of neurological disease therapeutics and the company's commitment to external business development opportunities, Fein tells investors in a research note.

ShowHide Related Items >><<
NBIX Neurocrine
$118.98 /

+3.91 (+3.40%)

NBIX Neurocrine
$118.98 /

+3.91 (+3.40%)

06/09/20 Wedbush
Wedbush bullish on Neurocrine, initiates with an Outperform
06/09/20 Oppenheimer
Neurocrine price target raised to $142 from $130 at Oppenheimer
06/08/20 Wedbush
Neurocrine initiated with an Outperform at Wedbush
05/04/20 Jefferies
Ingrezza sales trajectory still a reason to own Neurocrine, says Jefferies
NBIX Neurocrine
$118.98 /

+3.91 (+3.40%)

NBIX Neurocrine
$118.98 /

+3.91 (+3.40%)

Hot Stocks
Neurocrine, Takeda announce psychiatric disorder therapies collaboration » 07:08
06/16/20
06/16
07:08
06/16/20
07:08
NBIX

Neurocrine

$115.07 /

+ (+0.00%)

, TAK

Takeda Pharmaceutical

$18.38 /

-0.09 (-0.49%)

Neurocrine Biosciences…

Neurocrine Biosciences (NBIX) and Takeda Pharmaceutical (TAK) announced a strategic collaboration to develop and commercialize compounds in Takeda's early-to-mid-stage psychiatry pipeline. The companies said in a release, "Specifically, Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia. Under the terms of the agreement, Neurocrine Biosciences will be responsible for developing and commercializing all pipeline compounds included in the collaboration. Takeda will receive a total of $120 million in upfront cash. Additionally, Takeda will be entitled to development milestones of up to $495 million, commercial milestones of up to $1.4 billion and up to double-digit royalties on net sales. At certain development events, Takeda may elect to opt in or out of a 50:50 profit share on all clinical programs on an asset-by-asset basis. For any asset in which Takeda is participating in a 50:50 profit share arrangement, Takeda will not be eligible to receive development or commercial milestones."

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$18.38 /

-0.09 (-0.49%)

NBIX Neurocrine
$115.07 /

+ (+0.00%)

NBIX Neurocrine
$115.07 /

+ (+0.00%)

06/09/20 Wedbush
Wedbush bullish on Neurocrine, initiates with an Outperform
06/09/20 Oppenheimer
Neurocrine price target raised to $142 from $130 at Oppenheimer
06/08/20 Wedbush
Neurocrine initiated with an Outperform at Wedbush
05/04/20 Jefferies
Ingrezza sales trajectory still a reason to own Neurocrine, says Jefferies
TAK Takeda Pharmaceutical
$18.38 /

-0.09 (-0.49%)

04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
03/25/20 Stifel
Molecular Templates initiated with a Buy at Stifel
02/25/20 Stifel
Iovance among 'more interesting' cell therapy takeout candidates, says Stifel
TAK Takeda Pharmaceutical
$18.38 /

-0.09 (-0.49%)

NBIX Neurocrine
$115.07 /

+ (+0.00%)

TAK Takeda Pharmaceutical
$18.38 /

-0.09 (-0.49%)

TAK Takeda Pharmaceutical
$18.38 /

-0.09 (-0.49%)

NBIX Neurocrine
$115.07 /

+ (+0.00%)

TAK Takeda Pharmaceutical
$18.38 /

-0.09 (-0.49%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.